HAVCR2 and cancer: Since both pathways are involved in cancer-related immune exhaustion, double blockade of the PD-1/PD-L1 axis and TIM-3 pathway following locoregional treatments could promote the therapeutic outcome and improve the overall survival in patients with HCC.